MX2024011043A - Combinaciones terapéuticas, composiciones y métodos para diseñar y producir estados mentales entactogénos - Google Patents

Combinaciones terapéuticas, composiciones y métodos para diseñar y producir estados mentales entactogénos

Info

Publication number
MX2024011043A
MX2024011043A MX2024011043A MX2024011043A MX2024011043A MX 2024011043 A MX2024011043 A MX 2024011043A MX 2024011043 A MX2024011043 A MX 2024011043A MX 2024011043 A MX2024011043 A MX 2024011043A MX 2024011043 A MX2024011043 A MX 2024011043A
Authority
MX
Mexico
Prior art keywords
compositions
designing
methods
mental
therapeutic combinations
Prior art date
Application number
MX2024011043A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Ray
Original Assignee
Mindstate Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mindstate Design Labs Inc filed Critical Mindstate Design Labs Inc
Publication of MX2024011043A publication Critical patent/MX2024011043A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024011043A 2022-03-09 2024-09-09 Combinaciones terapéuticas, composiciones y métodos para diseñar y producir estados mentales entactogénos MX2024011043A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263318369P 2022-03-09 2022-03-09
PCT/US2023/014926 WO2023172701A2 (en) 2022-03-09 2023-03-09 Therapeutic combinations, compositions, and methods for designing and producing entactogenic mindstates

Publications (1)

Publication Number Publication Date
MX2024011043A true MX2024011043A (es) 2024-12-06

Family

ID=87935763

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011043A MX2024011043A (es) 2022-03-09 2024-09-09 Combinaciones terapéuticas, composiciones y métodos para diseñar y producir estados mentales entactogénos

Country Status (11)

Country Link
US (1) US20250177354A1 (cg-RX-API-DMAC7.html)
EP (1) EP4489649A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025509432A (cg-RX-API-DMAC7.html)
KR (1) KR20250011101A (cg-RX-API-DMAC7.html)
CN (1) CN119497589A (cg-RX-API-DMAC7.html)
AU (1) AU2023232712A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245622A1 (cg-RX-API-DMAC7.html)
CR (1) CR20240417A (cg-RX-API-DMAC7.html)
IL (1) IL315512A (cg-RX-API-DMAC7.html)
MX (1) MX2024011043A (cg-RX-API-DMAC7.html)
WO (1) WO2023172701A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250145285A (ko) * 2024-03-28 2025-10-13 건국대학교 글로컬산학협력단 릴메니딘을 포함하는 정서장애의 예방, 개선 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721978D0 (en) * 1997-10-17 1997-12-17 Lilly Co Eli Treatment of depression
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
WO2014004676A1 (en) * 2012-06-26 2014-01-03 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors as neuroprotective agents in the cns
US12414936B2 (en) * 2017-02-09 2025-09-16 Caamtech, Inc. Compositions comprising a serotonergic tryptamine compound

Also Published As

Publication number Publication date
CR20240417A (es) 2025-03-04
WO2023172701A3 (en) 2023-11-09
JP2025509432A (ja) 2025-04-11
US20250177354A1 (en) 2025-06-05
EP4489649A2 (en) 2025-01-15
IL315512A (en) 2024-11-01
WO2023172701A2 (en) 2023-09-14
EP4489649A4 (en) 2026-07-01
KR20250011101A (ko) 2025-01-21
CN119497589A (zh) 2025-02-21
AU2023232712A1 (en) 2024-10-17
CA3245622A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
CO2021005146A2 (es) Inhibidores selectivos de rgmc y el uso de los mismos
MX2024004921A (es) Derivados de piperidinilindol, metodos de preparacion y usos medicinales de estos.
CL2019000268A1 (es) Composición de cannabis.
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
PY2036977A (es) Derivados de cannabinoides como compuestos farmacéuticamente activos y métodos de preparación de los mismos
MX2021003110A (es) Agonistas del receptor x farnesoide y usos de los mismos.
CL2020002774A1 (es) Tratamiento combinado de fibrosis y/o angiogénesis ocular
CR8718A (es) Compuesto de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central
MX2019011606A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
MX2024013040A (es) Pirfenidona enriquecida con deuterio y metodos para su uso
MX2019013878A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
UY30829A1 (es) Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato
MX2019013893A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP21030482A (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
PA8680701A1 (es) Derivados de oxindol
CL2023000371A1 (es) Composiciones y métodos para inhibir la expresión de plp1.
DOP2023000223A (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
CO2020001012A2 (es) Compuestos bifuncionales
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
UY29735A1 (es) Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos